Page last updated: 2024-12-09

1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-(4-methoxyphenyl)sulfonylpiperazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You're asking about **1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-(4-methoxyphenyl)sulfonylpiperazine**. This is a complex organic molecule with a rather specific structure and a potential role in research, especially in the field of medicine.

Let's break down the name and its significance:

* **1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-(4-methoxyphenyl)sulfonylpiperazine**:
* **Piperazine**: This is a cyclic diamine that forms the backbone of the molecule. It's often used in the synthesis of pharmaceutical compounds.
* **Sulfonyl**: This refers to a group containing a sulfur atom double-bonded to two oxygen atoms (-SO2-). These groups are commonly found in pharmaceuticals and are known for their ability to bind to biological targets.
* **2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl**: This describes a specific substituent attached to the piperazine ring.
* **4-methoxyphenyl**: This indicates another substituent attached to the piperazine ring, a benzene ring with a methoxy group (CH3O-) at the 4th position.

**Why it might be important for research:**

* **Potential pharmacological activity:** Compounds with this type of structure are often investigated for their potential to interact with biological systems, especially those involving neurotransmission or enzymatic activity.
* **Potential drug development:** If the molecule shows desirable pharmacological properties, it might serve as a lead compound for the development of new drugs.
* **Chemical research:** It could be used as a building block for the synthesis of other, more complex molecules with potential applications in different fields.

**However, it's crucial to understand:**

* **No specific information about this particular molecule is readily available.** There's no published research or patent information that specifically mentions this compound. It's possible it hasn't been synthesized yet or hasn't been studied in detail.
* **The name itself suggests a complex structure:** This complexity might make its synthesis challenging and research into its properties less accessible.

**To find out more, you would need to:**

1. **Search specific chemical databases:** Look in databases like PubChem or Reaxys.
2. **Contact researchers in the field:** If you have a connection to researchers working with similar molecules or in drug development, they might have more information.
3. **Consult relevant scientific literature:** Search for publications related to piperazine derivatives, sulfonyl groups, and benzodioxin structures.

Remember, just because a compound has a specific structure doesn't automatically make it important or interesting. Research is needed to determine if it has any valuable properties or applications.

Cross-References

ID SourceID
PubMed CID650361
CHEMBL ID1088762
CHEBI ID92774
SCHEMBL ID1710881

Synonyms (26)

Synonym
OPREA1_442784
ml083
OPREA1_625841
ASN 05257430
MLS000888347
smr000004273
MLS000030964 ,
1-(2,3-dihydro-benzo[1,4]dioxine-6-sulfonyl)-4-(4-methoxy-benzenesulfonyl)-piperazine
dzg ,
1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine
NCGC00030335-02
NCGC00030335-03
DB07697
AKOS000703835
CHEMBL1088762
1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-(4-methoxyphenyl)sulfonylpiperazine
HMS2155M07
HMS3312H04
SCHEMBL1710881
HMS3604F06
CHEBI:92774
Z45413197
562867-96-3
Q27096916
bml283
1-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-4-((4-methoxyphenyl)sulfonyl)piperazine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.31620.044717.8581100.0000AID485294
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
Smad3Homo sapiens (human)Potency35.48130.00527.809829.0929AID588855
pyruvate kinase PKLR isoform 1 [Homo sapiens]Homo sapiens (human)Potency0.68161.41251.41251.4125AID1782
pyruvate kinase PKM isoform aHomo sapiens (human)Potency0.23400.04017.459031.6228AID1540; AID1631; AID1634; AID1751
pyruvate kinase PKLR isoform 2Homo sapiens (human)Potency1.67762.51194.65797.9433AID1781
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Pyruvate kinase PKMHomo sapiens (human)AC500.43050.03802.25409.1800AID476343; AID476347
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
programmed cell deathPyruvate kinase PKMHomo sapiens (human)
canonical glycolysisPyruvate kinase PKMHomo sapiens (human)
positive regulation of sprouting angiogenesisPyruvate kinase PKMHomo sapiens (human)
positive regulation of cytoplasmic translationPyruvate kinase PKMHomo sapiens (human)
glycolytic processPyruvate kinase PKMHomo sapiens (human)
cellular response to insulin stimulusPyruvate kinase PKMHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
magnesium ion bindingPyruvate kinase PKMHomo sapiens (human)
RNA bindingPyruvate kinase PKMHomo sapiens (human)
mRNA bindingPyruvate kinase PKMHomo sapiens (human)
protein tyrosine kinase activityPyruvate kinase PKMHomo sapiens (human)
pyruvate kinase activityPyruvate kinase PKMHomo sapiens (human)
protein bindingPyruvate kinase PKMHomo sapiens (human)
ATP bindingPyruvate kinase PKMHomo sapiens (human)
MHC class II protein complex bindingPyruvate kinase PKMHomo sapiens (human)
potassium ion bindingPyruvate kinase PKMHomo sapiens (human)
cadherin bindingPyruvate kinase PKMHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
extracellular regionPyruvate kinase PKMHomo sapiens (human)
nucleusPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
mitochondrionPyruvate kinase PKMHomo sapiens (human)
rough endoplasmic reticulumPyruvate kinase PKMHomo sapiens (human)
cytosolPyruvate kinase PKMHomo sapiens (human)
ciliumPyruvate kinase PKMHomo sapiens (human)
vesiclePyruvate kinase PKMHomo sapiens (human)
secretory granule lumenPyruvate kinase PKMHomo sapiens (human)
collagen-containing extracellular matrixPyruvate kinase PKMHomo sapiens (human)
extracellular exosomePyruvate kinase PKMHomo sapiens (human)
extracellular vesiclePyruvate kinase PKMHomo sapiens (human)
ficolin-1-rich granule lumenPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID476349Activation of PKM1 assessed as pyruvate formation by fluorescent pyruvate kinase-lactate dehydrogenase coupled assay2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID476499Activation of PKM2 assessed as reduction of Km for phosphoenolpyruvate relative to untreated control2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID476501Activation of PKM2 assessed as effect on Km for ADP relative to untreated control2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID476348Activation of PKM2 assessed as pyruvate formation by fluorescent pyruvate kinase-lactate dehydrogenase coupled assay relative to fructose-1,6-bis-phosphate2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID476344Activation of PKM2 assessed as ATP product formation at 57 uM by luminescent pyruvate kinase-luciferase coupled assay relative to fructose-1,6-bis-phosphate2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID476498Activation of PKL assessed as ATP product formation by luminescent pyruvate kinase-luciferase coupled assay relative to control2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID476496Activation of PKR assessed as ATP product formation by luminescent pyruvate kinase-luciferase coupled assay relative to control2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID476500Activation of PKM2 in presence of excess of phosphoenolpyruvate level2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID476495Activation of PKR assessed as pyruvate formation by fluorescent pyruvate kinase-lactate dehydrogenase coupled assay relative to control2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID476346Activation of Leishmania mexicana PKM2 by quantitative high throughput screening assay2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID476347Activation of PKM2 assessed as pyruvate formation by fluorescent pyruvate kinase-lactate dehydrogenase coupled assay2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID476343Activation of PKM2 assessed as ATP product formation by luminescent pyruvate kinase-luciferase coupled assay2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID476350Activation of PKM1 assessed as ATP product formation by luminescent pyruvate kinase-luciferase coupled assay2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID476497Activation of PKL assessed as pyruvate formation by fluorescent pyruvate kinase-lactate dehydrogenase coupled assay relative to control2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.41 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]